Valeant Prices $10.1B Bond Offering To Help Fund Salix Deal
Canadian drug giant Valeant Pharmaceuticals International Inc. on Friday priced an upsized $10.1 billion bond offering to fund its planned acquisition of Salix Pharmaceuticals Ltd., also being courted by rival Endo...To view the full article, register now.
Already a subscriber? Click here to view full article